Antithrombotic therapy after heart valve intervention: review of mechanisms, evidence and current guidance
Abstract
As the population ages and treatment options for heart valve disease increase, the number of patients with intracardiac valve prostheses is growing rapidly. Although all devices have the potential to cause thrombus formation, the propensity depends on the type of prosthesis as well as risk of the individual patient. Mechanical valve prostheses carry the highest (and persistent) risk of thromboembolism, and these patients require anticoagulation with vitamin K antagonists (warfarin). Required international normalised ratio levels are dependent on the location of the valve (mitral>aortic), type of valve (ball and cage vs bilealfet vs On-X bilealfet) and rhythm. The risk of tissue (biological) prosthesis is highest soon after surgery and is dependent on individual patient risk including age, valve location (mitral>aortic), history of thromboembolic events and rhythm. In patients with no other indication for anticoagulation, there is uncertainty on the benefits of anticoagulation versus antiplatelet therapy in patients with tissue prostheses or repaired native valves. Patients with an a priori indication for anticoagulation with a direct oral anticoagulant can continue taking this class of drug. Patients with transcatheter aortic valve implantation devices and no additional evidence-based indication for dual antiplatelet therapy or anticoagulation can be maintained on aspirin monotherapy. Patients undergoing transcatheter instrumentation in the mitral valve position should be anticoagulated, although there is currently no published evidence for antithrombotic management in this group of patients. Patients with thrombosed devices (commonly mitral mechanical) should preferably be treated surgically. Patients at high risk of thromboembolism (with mechanical prostheses) should undergo bridging therapy when undergoing surgery.Keywords
This publication has 29 references indexed in Scilit:
- Prevention of Thromboembolic Events After Bioprosthetic Aortic Valve ReplacementJACC, 2012
- Early Anticoagulation of Bioprosthetic Aortic Valves in Older PatientsJACC, 2012
- Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?Interactive CardioVascular and Thoracic Surgery, 2012
- Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient dataThe Lancet, 2012
- LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the “LOWERING-IT” TrialAmerican Heart Journal, 2010
- The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial FibrillationCirculation, 2009
- What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?Interactive CardioVascular and Thoracic Surgery, 2007
- AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart ValvesCirculation, 1996
- Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart ValvesNew England Journal of Medicine, 1995
- High risk of thromboemboli early after bioprosthetic cardiac valve replacementJACC, 1995